Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–16. https://doi.org/10.1038/nrc1014.
Article
CAS
PubMed
Google Scholar
Pottoo FH, Barkat MA, Harshita AMA, Javed MN, QMS J, et al. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Semin Cancer Biol. 2019;69:100.
Article
PubMed
Google Scholar
Whittle S, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17(4):369–86. https://doi.org/10.1080/14737140.2017.1285230.
Article
CAS
PubMed
Google Scholar
Malis J. Clinical presentation of neuroblastoma. Neuroblastoma. 2013. https://doi.org/10.5772/55921.
Brodeur GM, Bagatell R. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014;11(12):704–13. https://doi.org/10.1038/nrclinonc.2014.168.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Y, Tsai YH, Tseng BJ, Pan HY, Tseng SH, et al. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells. J Pediatr Surg. 2016;51(11):1818–25. https://doi.org/10.1016/j.jpedsurg.2016.07.003.
Article
PubMed
Google Scholar
Bilke S, Chen QR, Wei JS, Khan J. Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification. Clin Cancer Res. 2008;14(17):5540–7. https://doi.org/10.1158/1078-0432.CCR-07-4461.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–77. https://doi.org/10.1200/JCO.1993.11.8.1466.
Article
CAS
PubMed
Google Scholar
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289–97. https://doi.org/10.1200/JCO.2008.16.6785.
Article
PubMed
PubMed Central
Google Scholar
Leung CK. Fifteen years’ review of advanced childhood neuroblastoma from a single institution in Hong Kong. Chin Med J. 1998;111(5):466–9.
CAS
PubMed
Google Scholar
Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Paediatr Drugs. 2017;19(6):577–93. https://doi.org/10.1007/s40272-017-0251-3.
Article
PubMed
PubMed Central
Google Scholar
Xiaoli M, Mei J, Dawei Z, et al. Clinical features and recent treatment effect analysis of 91 neuroblastoma patients with multidisciplinary treatment. J Appl Clin Pediatr. 2013;28:178–82.
Google Scholar
Sidhu SK, Ramalingam K, Goyal S, Poonia M, Poonia M, Rajawat GS, et al. Comparing the efficacy of Leishman-Giemsa cocktail stain, Giemsa stain, and Papanicolaou stain in potentially malignant Oral lesions: a study on 540 cytological samples. JCytol. 2018;35:105–9.
Google Scholar
Amoroso L, Ognibene M, Morini M, Conte M, Cataldo AD, Tondo A, et al. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients. Genes Chromosom Cancer. 2020;59(5):277–85. https://doi.org/10.1002/gcc.22827.
Article
CAS
PubMed
Google Scholar
Lundberg G, Jin Y, Sehic D, Øra I, Versteeg R, Gisselsson D. Intratumour diversity of chromosome copy numbers in neuroblastoma mediated by on-going chromosome loss from a polyploid state. PLoS One. 2013;8(3):e59268. https://doi.org/10.1371/journal.pone.0059268.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lavarino C, Cheung NK, Garcia I, Domenech D, Torres C, Alaminos M, et al. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer. 2009;9(1):44. https://doi.org/10.1186/1471-2407-9-44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Parodi S, Pistorio A, Erminio G, Ognibene M, Morini M, Garaventa A, et al. Loss of whole chromosome X predicts prognosis of neuroblastoma patients with numerical genomic profile. Pediatr Blood Cancer. 2019;66(5):e27635. https://doi.org/10.1002/pbc.27635.
Article
CAS
PubMed
Google Scholar
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011;144(1):27–40. https://doi.org/10.1016/j.cell.2010.11.055.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang C, Feng Y, Zhang C, Cheng D, Wu R, Yang Y, et al. PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer. FASEB J. 2020;34(1):1304–18. https://doi.org/10.1096/fj.201901205RR.
Article
CAS
PubMed
Google Scholar
Leube B, Drechsler M, Mühlmann K, Schäfer R, Schulz WA, Santourlidis S, et al. Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate. 2002;50(3):135–44. https://doi.org/10.1002/pros.10038.
Article
CAS
PubMed
Google Scholar
Stiles BL. Phosphatase and tensin homologue deleted on chromosome 10: extending its PTEN tacles. Int J Biochem Cell Biol. 2009;41(4):757–61. https://doi.org/10.1016/j.biocel.2008.09.022.
Article
CAS
PubMed
Google Scholar
Li Z, Xie J, Fei Y, Gao P, Xie Q, Gao W, et al. GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN. Biochem Biophys Res Commun. 2019;510(3):339–44. https://doi.org/10.1016/j.bbrc.2018.12.169.
Article
CAS
PubMed
Google Scholar
Mora J, Cheung NK, Oplanich S, Chen L, Gerald WL. Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res. 2002;62(6):1761–7.
CAS
PubMed
Google Scholar
Stichel D, Ebrahimi A, Reuss D, Schrimpf D, Ono T, Shirahata M, et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol. 2018;136(5):793–803. https://doi.org/10.1007/s00401-018-1905-0.
Article
PubMed
Google Scholar
Lázcoz P, Muñoz J, Nistal M, Pestaña A, Encío IJ, Castresana JS. Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet. 2007;174(1):1–8. https://doi.org/10.1016/j.cancergencyto.2006.08.014.
Article
CAS
PubMed
Google Scholar
Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg. 2002;97(6):1397–401. https://doi.org/10.3171/jns.2002.97.6.1397.
Article
CAS
PubMed
Google Scholar
Park HS, Kim BC, Yeo HY, Kim KH, Yoo BC, Park JW, et al. Deleted in malignant brain tumor 1 is a novel prognostic marker in colorectal cancer. Oncol Rep. 2018;39(5):2279–87. https://doi.org/10.3892/or.2018.6287.
Article
CAS
PubMed
Google Scholar
Park AK, Kim P, Ballester LY, Esquenazi Y, Zhao Z. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma. Neuro-Oncology. 2019;21(1):59–70. https://doi.org/10.1093/neuonc/noy120.
Article
CAS
PubMed
Google Scholar
Jesionek-Kupnicka D, Braun M, Trąbska-Kluch B, Czech J, Szybka M, Szymańska B, et al. MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. Arch Med Sci. 2019;15(2):504–12. https://doi.org/10.5114/aoms.2017.69374.
Article
CAS
PubMed
Google Scholar
Campbell TM, Castro MAA, de Oliveira KG, Ponder BAJ, Meyer KB. ERα binding by transcription factors NFIB and YBX1 enables FGFR2 signaling to modulate estrogen responsiveness in breast Cancer. Cancer Res. 2018;78(2):410–21. https://doi.org/10.1158/0008-5472.CAN-17-1153.
Article
CAS
PubMed
Google Scholar
Huang Y, Hamana T, Liu J, Wang C, An L, You P, et al. Type 2 fibroblast growth factor receptor signaling preserves Stemness and prevents differentiation of prostate stem cells from the basal compartment. J Biol Chem. 2015;290(29):17753–61. https://doi.org/10.1074/jbc.M115.661066.
Article
CAS
PubMed
PubMed Central
Google Scholar
Stevens-Kroef M, Simons A, Rack K, Hastings RJ. Cytogenetic nomenclature and reporting. Methods Mol Biol. 2017;1541:303–9. https://doi.org/10.1007/978-1-4939-6703-2_24.
Article
CAS
PubMed
Google Scholar